secwatch.observer — SEC 8-K summary
======================================

Issuer:     TACTILE SYSTEMS TECHNOLOGY INC (TCMD)
CIK:        0001027838
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001104659-26-054869
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tactile Medical Q1 revenue up 23% to $75.3M; net loss narrows to $1.8M; raises FY2026 guidance
--------------------------------------------------------------------------------

- Revenue $75.3M (+23% YoY); lymphedema +23%, airway clearance +22%.
- Net loss $1.8M ($0.08 per share) vs $3.0M loss in Q1 2025; gross margin 76.5% vs 74%.
- Adjusted EBITDA $3.7M vs ($0.3M) loss a year ago.
- Raised FY2026 revenue guidance to $360-368M (prev $357-365M); adj EBITDA reaffirmed at $49-51M.
- Received FDA 510(k) clearance for next-gen AffloVest; acquired LymphaTech for lymphedema diagnostics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1027838/000110465926054869/0001104659-26-054869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1027838/000110465926054869/tcmd-20260504x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-054869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer